WallStreetZenWallStreetZen

NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Faisal Ghiath SukhtianDirector2026-07-2995,398$1.05
$99.98kBuy
Yezan Munther HaddadinDirector2026-06-0229,000$0.83
$24.16kBuy
Ghiath M. SukhtianDirector2026-05-288,539,709$0.59
$5.00MBuy
Faisal Ghiath SukhtianDirector2026-05-27122,174$0.41
$49.97kBuy
Yezan Munther HaddadinDirector2026-05-2634,000$0.44
$14.96kBuy
Kurt J. HilzingerDirector2026-05-26400,000$0.44
$176.40kBuy
Randy H. ThurmanDirector2026-05-265,000$0.43
$2.15kBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian76.23%92,139,272$101.35MInsider
Faisal Ghiath Sukhtian46.36%56,037,758$61.64MInsider
Biolexis Pte Ltd21.05%25,443,159$27.99MInsider
Arun Kumar Pillai19.02%22,982,529$25.28MInsider
Pankaj Mohan6.85%8,285,115$9.11MInsider
Armistice Capital LLC3.45%4,168,000$4.58MInstitution
Vanguard Capital Management LLC1.63%1,967,160$2.16MInstitution
Syntone Ventures LLC1.41%1,705,438$1.88MInsider
Jeff Evanson0.67%808,459$889.30kInsider
Terry Dagnon0.54%653,058$718.36kInsider

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK4.87%95.13%Net BuyingNet Buying
ANIX14.96%80.46%Net BuyingNet Buying
GUTS45.24%18.38%Net BuyingNet Buying
COYA34.67%9.20%Net Buying
ATHE0.00%0.17%
View Top Biotech Stocks

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 8.87% institutional shareholders, 173.35% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 92.14M shares representing 76.23% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $81.91M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.